Khong Jwu Jin, McNab Alan A, Ebeling Peter R, Craig Jamie E, Selva Dinesh
North West Academic Centre, The University of Melbourne, Western Hospital, St Albans, Victoria, Australia Orbital Plastics and Lacrimal Unit, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia Austin Health, Department of Surgery, University of Melbourne, Heidelberg, Victoria, Australia.
Orbital Plastics and Lacrimal Unit, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia Centre of Eye Research Australia, University of Melbourne, East Melbourne, Victoria, Australia.
Br J Ophthalmol. 2016 Jan;100(1):142-50. doi: 10.1136/bjophthalmol-2015-307399. Epub 2015 Nov 13.
Orbital changes in thyroid orbitopathy (TO) result from de novo adipogenesis, hyaluronan synthesis, interstitial oedema and enlargement of extraocular muscles. Cellular immunity, with predominantly CD4+ T cells expressing Th1 cytokines, and overexpression of macrophage-derived cytokines, perpetuate orbital inflammation. Orbital fibroblasts appear to be the major effector cells. Orbital fibroblasts express both thyrotropin receptor (TSHR) and insulin-like growth factor-1 receptor (IGF-1R) at higher levels than normal fibroblasts. TSHR expression increases in adipogenesis; TSHR agonism enhances hyaluronan production. IGF-1R stimulation leads to adipogenesis, hyaluronan synthesis and production of the chemokines, interleukin (IL)-16 and Regulated on Activation, Normal T Cell Expression and Secreted, which facilitate lymphocyte trafficking into the orbit. Immune activation uses a specific CD40:CD154 molecular bridge to activate orbital fibroblasts, which secrete pro-inflammatory cytokines including IL-1β, IL-1α, IL-6, IL-8, macrophage chemoattractant protein-1 and transforming growth factor-β, to perpetuate orbital inflammation. Molecular pathways including adenylyl cyclase/cyclic adenosine monophosphate, phophoinositide 3 kinase/AKT/mammalian target of rapamycin, mitogen-activated protein kinase are involved in TO. The emergence of a TO animal model and a new generation of TSHR antibody assays increasingly point towards TSHR as the primary autoantigen for extrathyroidal orbital involvement. Oxidative stress in TO resulting from imbalances of the oxidation-reduction state provides a framework of understanding for smoking prevention, achieving euthyroidism and the use of antioxidants such as selenium. Progress has been made in the understanding of the pathogenesis of TO, which should advance development of novel therapies targeting cellular immunity, specifically the CD40:CD40 ligand interaction, antibody-producing B cells, cytokines, TSHR and IGF-1R and its signalling pathways. Further studies in signalling networks and molecular triggers leading to burnout of TO will further our understanding of TO.
甲状腺眼病(TO)的眼眶改变源于新生脂肪形成、透明质酸合成、间质水肿和眼外肌增大。以主要表达Th1细胞因子的CD4 + T细胞为主的细胞免疫以及巨噬细胞衍生细胞因子的过表达使眼眶炎症持续存在。眼眶成纤维细胞似乎是主要效应细胞。眼眶成纤维细胞表达促甲状腺激素受体(TSHR)和胰岛素样生长因子-1受体(IGF-1R)的水平高于正常成纤维细胞。TSHR表达在脂肪形成过程中增加;TSHR激动作用增强透明质酸产生。IGF-1R刺激导致脂肪形成、透明质酸合成以及趋化因子、白细胞介素(IL)-16和活化调节正常T细胞表达和分泌因子的产生,这些因子促进淋巴细胞向眼眶的迁移。免疫激活利用特定的CD40:CD154分子桥激活眼眶成纤维细胞,后者分泌包括IL-1β、IL-1α、IL-6、IL-8、巨噬细胞趋化蛋白-1和转化生长因子-β在内的促炎细胞因子,使眼眶炎症持续存在。包括腺苷酸环化酶/环磷酸腺苷、磷脂酰肌醇3激酶/AKT/雷帕霉素哺乳动物靶蛋白、丝裂原活化蛋白激酶在内的分子途径参与甲状腺眼病。甲状腺眼病动物模型的出现和新一代TSHR抗体检测越来越多地表明TSHR是甲状腺外眼眶受累的主要自身抗原。氧化还原状态失衡导致的甲状腺眼病中的氧化应激为预防吸烟、实现甲状腺功能正常以及使用硒等抗氧化剂提供了一个理解框架。在甲状腺眼病发病机制的理解方面已经取得进展,这应该会推动针对细胞免疫,特别是CD40:CD40配体相互作用、产生抗体的B细胞、细胞因子、TSHR和IGF-1R及其信号通路的新型疗法的开发。对导致甲状腺眼病倦怠的信号网络和分子触发因素的进一步研究将加深我们对甲状腺眼病的理解。